TThe broader medical sector should now be in the spotlight on increased demand for the coronavirus vaccine as well as treatment as the Delta variant of COVID-19 fear increases. Apart from that, bullish earnings and a decent valuation should give the sector new impetus.
Optimistic profits, sales linked to Covid-19
Healthcare sector earnings expectations are optimistic as the sector is expected to register 14.6% growth in the second quarter of 2021 on revenue growth of 15.7%, according to earnings trends published on July 14, 2021.
A higher demand for drugs, tests and vaccines for COVID-19 is a plus for the industry. Roche’s first half net profit increases 2% to 8.22 billion Swiss francs (8.96 billion francs) and sales increased 8% at constant exchange rates to 30.71 billion francs better than expected.
Sales of the Diagnostics division grew 51% in the first half of the year due to strong demand for Covid-19 testing and strong momentum in routine testing, the drug maker said. This helped offset a 3% drop in sales of pharmaceutical products.
Johnson & Johnson (JNJ) has raised its overall revenue estimate for the year and forecasts $ 2.5 billion in sales of its COVID-19 vaccine while Pfizer and Moderna estimate $$ 26 billion and $ 19.2 billion in annual sales of their vaccines, respectively.
More recently, Moderna MRNA, known for its success in the COVID-19 vaccine, has entered the big leagues with its addition to the S&P 500 Index. Share has risen nearly 175% this year last week, leading to Moderna’s market valuation of over $ 115 billion (read: Moderna takes off for inclusion in the S&P 500: focus on ETFs).
Against this background, we present below a few healthcare ETFs that are hovering around an all-time high.
Focus on ETFs
Alphadex First Trust Healthcare ETFs FXH
The underlying StrataQuant Health Care Index uses the AlphaDEX stock selection methodology to select stocks for the Russell 1000 Index. Medical Equipment and Services (45.44%), Pharmaceuticals and Biotechnology (32.44 %) and healthcare providers (22.12%) are the top three holdings of the fund. The fund charges 61 basis points in fees.
ETF US Healthcare iShares IYH
The underlying Dow Jones US Health Care Index measures the performance of the healthcare sector in the US stock market. The fund charges 43 basis points in fees. Pharmaceuticals (26.02%), healthcare equipment (24.84%), biotechnology (16.63%), managed healthcare (11.42%) and science tools and services of life (10.19%) are the five main sectors of the fund (read: 2 sector ETFs oscillating around historic highs).
ETF Innovative Healthcare iShares Evolved in the United States IEIH
This ETF is active and does not track a benchmark. The fund seeks to provide access to US companies with innovative healthcare exposure, ranked using a proprietary rating system. The fund charges 18 basis points of fees (read: JNJ beats second quarter earnings, view up: ETFs to buy).
Biotech Vaneck ETF BBH
The underlying MVIS US Listed Biotech 25 index tracks the overall performance of companies involved in the development and production, marketing and sale of drugs based on genetic analysis and diagnostic equipment. The fund charges 35 basis points in fees.
Boom in infrastructure stocks will sweep America
A massive push to rebuild crumbling American infrastructure will soon be underway. It is bipartisan, urgent and inevitable. Billions will be spent. Fortunes will be made.
The only question is, “Are you going to jump into good stocks early when they have the greatest potential for growth?” “
Zacks published a special report to help you do just that, and today it’s free. Discover 7 special companies looking to make the most of the construction and repair of roads, bridges and buildings, as well as transporting goods and transforming energy on an almost unimaginable scale.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.